Cargando…

Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study

Introduction: Level I evidence supports the use of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer prior to radical cystectomy (RC). On average, 30–40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC. Some centers risk-strati...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Rundstedt, Friedrich-Carl, Mata, Douglas A., Kryvenko, Oleksandr N., Shah, Anup A., Jhun, Iny, Lerner, Seth P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271426/ https://www.ncbi.nlm.nih.gov/pubmed/28149933 http://dx.doi.org/10.3233/BLC-160062

Ejemplares similares

Bacille-Calmette-Guerin non-responders: how to manage
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2015)

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer
por: Garczyk, Stefan, et al.
Publicado: (2021)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2016)

Changes in neoadjuvant chemotherapy utilization in muscle invasive bladder cancer treatment: a tertiary center retrospective study
por: Gronostaj, Katarzyna, et al.
Publicado: (2020)

Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy
por: Bhat, Abhishek, et al.
Publicado: (2019)

Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
por: Jayaratna, Isuru S., et al.
Publicado: (2015)

Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report
por: Prelaj, Arsela, et al.
Publicado: (2016)

Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
por: Sherif, Amir, et al.
Publicado: (2018)

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer
por: Carvalho, Filipe LF., et al.
Publicado: (2020)

Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Miyagi, Hiroko, et al.
Publicado: (2022)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Corrigendum to “Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy”
por: Bhat, Abhishek, et al.
Publicado: (2019)

Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer
por: King, Daniel A., et al.
Publicado: (2020)

Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
por: Au, Daniel, et al.
Publicado: (2021)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
por: Cowan, N. G., et al.
Publicado: (2014)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Utilization of Neoadjuvant Chemotherapy Varies in the Treatment of Women with Invasive Breast Cancer
por: Onitilo, Adedayo A., et al.
Publicado: (2013)

The “Guidewire-Coil”-Technique to prevent retrograde stone migration of ureteric calculi during intracorporeal lithothripsy
por: Dreger, Nici Markus, et al.
Publicado: (2017)

Understanding PSA and its derivatives in prediction of tumor volume: addressing health disparities in prostate cancer risk stratification
por: Chinea, Felix M, et al.
Publicado: (2017)

The impact of weather changes on air quality and health in the United States in 1994–2012
por: Jhun, Iny, et al.
Publicado: (2015)

Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?
por: Nguyen, Huyen T., et al.
Publicado: (2017)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience
por: Yu, Bin, et al.
Publicado: (2015)

Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Marcq, Gautier, et al.
Publicado: (2019)

Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
por: Font, Albert, et al.
Publicado: (2020)

Metabolic Profiling of Bladder Cancer Patients’ Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy
por: Zhuang, Juntao, et al.
Publicado: (2022)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer
por: Baird, Bryce, et al.
Publicado: (2023)

Editorial Comment: Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients
por: Korkes, Fernando
Publicado: (2021)

The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy
por: Pereyra, D., et al.
Publicado: (2019)

Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
por: Prakash, Ipshita, et al.
Publicado: (2022)

Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group
por: Dobé, Tom-Régis, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9eq42bagl18ja7tlkvr2apgpqh